Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Letrozole Treatment to Normalize Serum Testosterone in Men with Hypogonadotropic Hypogonadism due to Pituitary Damage
2006-002304-33Phase 2Active
- Sponsor
- Rijnstate
- Start
- Jul 2006
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of letrozole in hypogonadotropic hypogonadism (HH) and pituitary diseases, sponsored by Rijnstate. Primary endpoint: Minimal effective dose to normalize serum testosterone. Started Jul 2006; status: active.
02
Drugs
letrozole
03
Conditions
hypogonadotropic hypogonadism (HH)pituitary diseases
Beyond the preview
Go deeper on 2006-002304-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-002304-33.